This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Abiomed Dirección
Dirección controles de criterios 4/4
Información clave
Mike Minogue
Chief Executive Officer (CEO)
US$12.7m
Compensación total
| Porcentaje del salario del CEO | 6.2% |
| Permanencia del CEO | 18.7yrs |
| Participación del CEO | 0.8% |
| Permanencia media de la dirección | 4.5yrs |
| Promedio de permanencia en la Junta Directiva | 8.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Abiomed (NASDAQ:ABMD) Has More To Do To Multiply In Value Going Forward
Oct 24
Abiomed's Impella low profile sheath gets FDA clearance
Oct 17Abiomed: Correction Offers Good Buying Opportunity
Sep 28U.S. FDA gives two approvals to Abiomed Impella heart pumps
Sep 16What Does Abiomed, Inc.'s (NASDAQ:ABMD) Share Price Indicate?
Sep 13Abiomed FQ1 2023 Earnings Preview
Aug 03Returns On Capital At Abiomed (NASDAQ:ABMD) Have Stalled
Jul 11Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages
May 17Is Abiomed (NASDAQ:ABMD) A Risky Investment?
Mar 17Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk
Jan 24The Returns At Abiomed (NASDAQ:ABMD) Aren't Growing
Jan 04These 4 Measures Indicate That Abiomed (NASDAQ:ABMD) Is Using Debt Safely
Dec 14Abiomed: Impella Will Continue To Drive Revenue Growth
Sep 10Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return
Sep 01Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating
Jul 13At US$335, Is It Time To Put Abiomed, Inc. (NASDAQ:ABMD) On Your Watch List?
Jul 08DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue
Jun 08Abiomed acquires preCARDIA a company targeting acute heart failure
Jun 01Here's Why I Think Abiomed (NASDAQ:ABMD) Might Deserve Your Attention Today
May 16Boston Scientific’s new clinical trial can impact Abiomed: Raymond James
May 06Abiomed FQ4 2021 Earnings Preview
Apr 28Should You Investigate Abiomed, Inc. (NASDAQ:ABMD) At US$315?
Apr 02Abiomed, Inc.'s (NASDAQ:ABMD) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Mar 12Has Abiomed (NASDAQ:ABMD) Got What It Takes To Become A Multi-Bagger?
Feb 18Results: Abiomed, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Jan 31Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | US$267m |
| Jun 30 2022 | n/a | n/a | US$218m |
| Mar 31 2022 | US$13m | US$789k | US$137m |
| Dec 31 2021 | n/a | n/a | US$133m |
| Sep 30 2021 | n/a | n/a | US$149m |
| Jun 30 2021 | n/a | n/a | US$154m |
| Mar 31 2021 | US$15m | US$608k | US$226m |
| Dec 31 2020 | n/a | n/a | US$200m |
| Sep 30 2020 | n/a | n/a | US$208m |
| Jun 30 2020 | n/a | n/a | US$159m |
| Mar 31 2020 | US$17m | US$768k | US$203m |
| Dec 31 2019 | n/a | n/a | US$245m |
| Sep 30 2019 | n/a | n/a | US$221m |
| Jun 30 2019 | n/a | n/a | US$258m |
| Mar 31 2019 | US$19m | US$753k | US$259m |
| Dec 31 2018 | n/a | n/a | US$222m |
| Sep 30 2018 | n/a | n/a | US$190m |
| Jun 30 2018 | n/a | n/a | US$165m |
| Mar 31 2018 | US$10m | US$718k | US$112m |
| Dec 31 2017 | n/a | n/a | US$90m |
| Sep 30 2017 | n/a | n/a | US$92m |
| Jun 30 2017 | n/a | n/a | US$77m |
| Mar 31 2017 | US$12m | US$649k | US$52m |
| Dec 31 2016 | n/a | n/a | US$48m |
| Sep 30 2016 | n/a | n/a | US$43m |
| Jun 30 2016 | n/a | n/a | US$42m |
| Mar 31 2016 | US$19m | US$630k | US$38m |
Compensación vs. Mercado: Mike's total compensation ($USD12.67M) is about average for companies of similar size in the US market ($USD12.79M).
Compensación vs. Ingresos: Mike's compensation has been consistent with company performance over the past year.
CEO
Mike Minogue (55 yo)
18.7yrs
Permanencia
US$12,665,992
Compensación
Mr. Michael R. Minogue, also known as Mike, served as Director at Medical Device Innovation Consortium, previously served as its chairman until June 2019. He has been Chief Executive Officer and President...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 18.7yrs | US$12.67m | 0.77% $ 133.2m | |
| Executive VP & CFO | 4.7yrs | US$3.04m | 0.017% $ 2.9m | |
| Executive VP | 4.5yrs | US$2.57m | 0.027% $ 4.7m | |
| Executive VP & Chief Commercial Officer | 2.7yrs | US$2.84m | 0.045% $ 7.8m | |
| Scientific & Technology Advisor | less than a year | US$2.29m | 0.30% $ 52.2m | |
| Executive Vice President of Global Operations & Integration | no data | sin datos | 0.017% $ 3.0m | |
| Executive VP & Chief Technology Officer | no data | sin datos | sin datos | |
| Director of Investor Relations | 8.3yrs | sin datos | sin datos | |
| Communications Manager | no data | sin datos | sin datos | |
| VP & GM of Global Sales | 13.8yrs | US$1.71m | sin datos | |
| VP & Chief Human Resources Officer | 3.3yrs | sin datos | sin datos | |
| Executive VP & Chief Medical Officer | 2.5yrs | sin datos | sin datos |
4.5yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: ABMD's management team is considered experienced (4.5 years average tenure).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 18.7yrs | US$12.67m | 0.77% $ 133.2m | |
| Independent Director | 14.6yrs | US$266.80k | 0.26% $ 45.2m | |
| Independent Director | 6.8yrs | US$266.80k | 0.021% $ 3.5m | |
| Independent Director | 11.6yrs | US$269.30k | 0.013% $ 2.2m | |
| Independent Director | 8.3yrs | US$259.30k | 0.032% $ 5.5m | |
| Independent Lead Director | 19.3yrs | US$299.30k | 0.032% $ 5.4m | |
| Independent Director | 1.7yrs | US$499.89k | 0.0011% $ 190.8k | |
| Independent Director | 6.8yrs | US$264.30k | 0.015% $ 2.6m | |
| Independent Director | 1.8yrs | US$259.30k | 0.0011% $ 195.9k |
8.3yrs
Permanencia media
67yo
Promedio de edad
Junta con experiencia: ABMD's board of directors are considered experienced (8.3 years average tenure).